CAPRICOR THERAPEUTICS INC
CAPRNASDAQ🏆 #3105 by market capEarnings Nov 17US Equity
$6.23▲ $0.14 (+2.30%)
Pre-market · at closeTrack CAPR
Get earnings, price moves & breaking news on Telegram
24h▲ 2.3%
7d▲ 1.7%
14d▼ 14.2%
30d▼ 27.4%
ytd▼ 78.4%
1y▼ 10.1%
🏦Market Cap
$362M
Small Cap
📈Revenue Growth (YoY)
—
📊Gross Margin
—
💵FCF Margin
16.9%
Healthy
⚖️P/S Ratio
16.6x
Expensive
Otter Score
—
Insufficient data
Trading Snapshot
- Day Range
- $5.93 – $6.41
- 52-Week Range
- $2.96 – $40.37
- Volume (shares)
- 172,917
- Avg Volume (shares)
- —
- Shares Outstanding
- 58.1M
- Next Earnings
- 2026-11-17
Fundamentals Snapshot
- Annual Revenue
- —
- Last Q Revenue
- —
- P/E Ratio
- —
- P/S Ratio
- 16.6x
- EPS (TTM)
- $-2.45
- Dividend Yield
- —
- Dilution (1yr)
- +38.7%
CAPRICOR THERAPEUTICS INC
CAPRFinancial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0▼ −100.0% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
-124.4%▲ +177.9% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$108M▲ +154.1% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$73M▲ +75.1% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
48.9M▲ +38.7% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$270M▲ +$263M YoY
StockOtter · stockotter.spaceAbout CAPRICOR THERAPEUTICS INC
Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.
🦦
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Insufficient data for all five components.
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Insufficient data
—/100
Analyst data unavailable.
Latest News & Updates
News unavailable.